Health Advocates Issue One-Year Report Card on Addyi, the Female Libido Drug

FOR IMMEDIATE RELEASE Contact: Shaniqua Seth at sseth@nwhn.org or 202.682-2640, ext. 225 WASHINGTON, DC – August 18th marks the one-year anniversary of the Food and Drug Administration’s (FDA) approval of flibanserin (brand name: Addyi), the so-called “female Viagra” pill. In light of recent developments, the National Women’s Health Network (NWHN) has issued a one-year report … Continued

Addyi Report: One Year Later!

One year ago today, the FDA buckled to pressure from a savvy astroturf campaign and approved the female libido drug flibanserin (brand name: Addyi). In response, we launched the “Pass on the Pink Pill – Or Pass Out” campaign to warn women of the marginal benefits and serious side effects of the “pink pill”—complications like … Continued

Addyi 1 Year Later: What’s the Score?

Click image to download PDF of the report card Report Card References 1 – Addyi’s FDA Warning Addyi’s life-threatening side effects were so grave that they warranted the strictest possible warning by the FDA—a “black box warning.” Those side effects include severe, sudden drops in blood pressure that can lead to loss of consciousness for … Continued